Nasdaq ikna.

Nov 29, 2023 · The public float for IKNA is 25.79M and currently, short sellers hold a 4.01% ratio of that float. The average trading volume of IKNA on November 29, 2023 was 174.06K shares. IKNA) stock’s latest price update. Ikena Oncology Inc (NASDAQ: IKNA)’s stock price has dropped by -10.56 in relation to previous closing price of 1.61.

Nasdaq ikna. Things To Know About Nasdaq ikna.

30 minutes. No description. Ikena™ is redefining the targeted oncology landscape and envisions a world in which every cancer patient has a cure. We develop therapies that target the underlying mechanisms driving cancer survival and growth.According to NASDAQ, as of May 2014, the highest NASDAQ closing ever was achieved on March 9, 2000, when the market closed at a record 5046.86. USA Today reports that the highest closing achieved by NASDAQ since was a 4007.09 closing on Nov...Nov 7, 2022 · Third Quarter 2022 Financial Results. As of September 30, 2022, Ikena had $174.4 million in cash, cash equivalents, and marketable securities, and believes this will be sufficient to meet its ... Nov 28, 2022 · BOSTON, Nov. 28, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced ...

Nov 28, 2022 · BOSTON, Nov. 28, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced ... May 18, 2023 · IKNA has a market cap of $253mn and a cash balance of $157mn. Research and development expenses were $64.3 million for the year ended December 31, 2022 and general and administrative expenses were ... Acquisition Corp. (NASDAQ: INKA) announced it has entered into a business combination agreement with Near Intelligence Holdings, Inc. in a de-SPAC transaction On November 14, 2022. TLG Acquisition One Corp. (NYSE: TLGA) announced it has entered into a business combination agreement with ElectrIQ Power, Inc. in a de-SPAC transaction FAIRNESS …

The latest price target for . Ikena Oncology (NASDAQ: IKNA) was reported by HC Wainwright & Co. on Thursday, November 9, 2023.The analyst firm set a price target for 11.00 expecting IKNA to rise ...BOSTON, May 12, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced ...

Ikena acquired all of Pionyr’s assets, including approximately $43 million in net cash, in exchange for shares of IKNA stock, in a combination of common stock and non-voting convertible ...BOSTON, May 15, 2023 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”, “Company”), a targeted oncology company forging new territory in patient-directed cancer treatment ...Ikena Oncology, Inc. (IKNA) Reports Q2 Loss, Lags Revenue Estimates. Zacks • Aug 10, 2023. Kronos Bio, Inc. (KRON) Reports Q2 Loss, Misses Revenue Estimates.Ikena Oncology, Inc. (NASDAQ:IKNA) is a Boston, Massachusetts-based company with a strong pipeline. Ikena Oncology, Inc. (NASDAQ:IKNA) went public in 2021. In November last year, Ikena Oncology, Inc.

Find the latest Financials data for Ikena Oncology, Inc. Common Stock (IKNA) at Nasdaq.com.

Tesla, Inc. (NASDAQ:TSLA) rose 4.4% to close at $691.05 as the company reported that it has delivered 184,800 vehicles in the first quarter, handily exceeding the 168,000 number analysts expected.

Risk Analysis Highly volatile share price over the past 3 months Earnings are forecast to decline by an average of 10.5% per year for the next 3 years Does not have a …He is a director and co-founder of IFM Therapeutics, Intellia Therapeutics (NASDAQ: NTLA) and Triplet Therapeutics. Jean-François also serves on the boards of Ikena Oncology (NASDAQ: IKNA) and Scorpion Therapeutics. Some of his prior investments include Arteaus Therapeutics (acquired by Eli Lilly), CoStim Pharmaceuticals (acquired by …Nasdaq Fund Secondaries; Featured Solutions Nasdaq's IPO Process; ETF Listings; Nasdaq-100 Index Options; Derivatives AcademyGainers DiamondHead Holdings Corp. (NASDAQ: DHHC) shares jumped 104.2% to $21.15. DiamondHead entered into convertible note purchase agreement dated March 21, 2023.Ikena acquired all of Pionyr’s assets, including approximately $43 million in net cash, in exchange for shares of IKNA stock, in a combination of common stock and non-voting convertible ...

BOSTON, Oct. 05, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced ...BOSTON, June 22, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced ...BOSTON, March 07, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA), a targeted oncology company navigating new territory in patient-directed cancer treatment, today announced that it ...... (IKNA). Nov. 9, 2023 at 2:09 p.m. ET on TipRanks.com. Buy Recommendation for ... Real-time last sale data for U.S. stock quotes reflect trades reported through ...30 minutes. No description. Ikena™ is redefining the targeted oncology landscape and envisions a world in which every cancer patient has a cure. We develop therapies that target the underlying mechanisms driving cancer survival and growth. Near is among the largest full-stack intelligence providers of aggregated anonymized data on people's behavior around places, with 1.6 billion unique user IDs, in over 70 million places across 44 ...

BOSTON, May 12, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced ...

Dec 1, 2023 · In the previous quarter, Ikena Oncology (NASDAQ:IKNA) reported ($0.40) earnings per share (EPS) to beat the analysts' consensus estimate of ($0.44) by $0.04. Learn more on analysts' earnings estimate vs. IKNA's actual earnings. BOSTON, Nov. 10, 2021 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”, “Company”), a targeted oncology company focused on developing novel cancer therapies targeting key ...He focuses on private company investments and fundraising for the firm. Mr. Draetta currently serves on the board of Chord Therapeutics and is Chief Financial Officer of Omega Alpha SPAC (NASDAQ ...BOSTON, Nov. 28, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced ...BOSTON, March 01, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA), a targeted oncology company navigating new territory in patient-directed cancer treatment, today announced that ...Nov 20, 2023 · The stock of Ikena Oncology Inc (NASDAQ: IKNA) has increased by 20.81 when compared to last closing price of 1.49.Despite this, the company has seen a gain of 23.29% in its stock price over the last five trading days. Zacks Investment Research reported 2023-06-20 that Ikena Oncology, Inc. (IKNA) could be a great choice for investors looking to ... BOSTON, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” “Company”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced that management will participate in three upcoming investor conferences in November.. Details are as follows: Stifel Healthcare Conference, …Ikena Oncology Inc. analyst ratings, historical stock prices, earnings estimates & actuals. IKNA updated stock price target summary.

According to the issued ratings of 4 analysts in the last year, the consensus rating for Ikena Oncology stock is Buy based on the current 4 buy ratings for IKNA. The average twelve-month price prediction for Ikena Oncology is $11.67 with a high price target of $13.00 and a low price target of $11.00. Learn more on IKNA's analyst rating history.

Company shares further detail on the differentiators of IK-930, a TEAD-paralog selective inhibitor. BOSTON, Oct. 18, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a ...

Ikena Oncology (NASDAQ:IKNA) and Sangamo Therapeutics (NASDAQ:SGMO) are both small-cap medical companies, but which is the superior investment?We will contrast the two companies based on the strength of their media sentiment, analyst recommendations, dividends, community ranking, earnings, profitability, valuation, institutional ownership and risk.BOSTON, Nov. 10, 2021 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”, “Company”), a targeted oncology company focused on developing novel cancer therapies targeting key ...Nkarta, Inc. Common Stock (NKTX) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.The three major U.S. stock exchanges are the New York Stock Exchange (NYSE), the NASDAQ and the American Stock Exchange (AMEX). As of 2014, the NYSE is the largest and most prestigious of the three. The NASDAQ is a virtual stock exchange.BOSTON, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” “Company”), a targeted oncology company forging new territory in patient-directed cancer treatment ...BOSTON, Oct. 01, 2021 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA), a targeted oncology company navigating new territory in patient-directed cancer treatment, today announced that three ...23 mai 2023 ... Dolar, Borsa, Altın, Eurobond, Bankalar ve Nasdaq Hakkında ... İlahiyatçı Kızlar Celal Şengör'ü "Bir Yaratan" Olduğuna İkna Etmeye Çalışıyorlar.BOSTON, Nov. 28, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced ...Hollanda’da 22 Kasım'da yapılan erken genel seçimde ülkenin ilk kadın başbakanı olmak için yarışan ancak büyük bir yenilgi alan Özgürlük ve Demokrasi İçin …Find the latest Financials data for Ikena Oncology, Inc. Common Stock (IKNA) at Nasdaq.com.

Nov 7, 2023 · BOSTON, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” “Company”), a targeted oncology company forging new territory in patient-directed cancer treatment ... BOSTON, May 15, 2023 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”, “Company”), a targeted oncology company forging new territory in patient-directed cancer treatment ...Formula One Group (NASDAQ:FWONA) has seen a decrease in hedge fund sentiment lately. Formula One Group (NASDAQ: FWONA ) was in 19 hedge funds' portfolios at the end of the first quarter of 2021 ...Instagram:https://instagram. high dividend reitbank loan etfukraine hryvniahow do i get into day trading The public float for IKNA is 25.79M and currently, short sellers hold a 4.01% ratio of that float. The average trading volume of IKNA on November 29, 2023 was 174.06K shares. IKNA) stock’s latest price update. Ikena Oncology Inc (NASDAQ: IKNA)’s stock price has dropped by -10.56 in relation to previous closing price of 1.61.May 12, 2022 · First Quarter 2022 Financial results. Ikena had $212.4 million in cash, cash equivalents, marketable securities as of March 31, 2022, as compared to $232.2 million as of December 31, 2021. Ikena ... onetest vs galleripolestar vs lucid Advancement across Company’s pipeline towards regulatory and data milestonesBOSTON, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology ...IKNA Edit my quotes Ikena Oncology, Inc. Common Stock (IKNA) Add to Watchlist Add to Portfolio Quotes Summary Real-Time After-Hours Pre-Market Charts NEWS & … smartasset financial advisor reviews The latest price target for . Ikena Oncology (NASDAQ: IKNA) was reported by HC Wainwright & Co. on November 9, 2023.The analyst firm set a price target for $11.00 expecting IKNA to rise to within ...List with Nasdaq; Nasdaq Private Market; Nasdaq Fund Secondaries; Investor Relations Intelligence ; Nasdaq Direct Listings; Optimize Governance Practices. Board Portal …